Merck KGaA partners with BenevolentAI and Exscientia for AI-driven drug discovery
TL;DR
Merck KGaA has entered into separate AI drug discovery partnerships with BenevolentAI and Exscientia, focusing on targets in oncology, neurology, and immunology. Exscientia will receive $20 million upfront for each of the three projects, with a total deal value of $674 million across all milestones. BenevolentAI will receive a low double-digit million dollar payment upfront, potentially worth $594 million, and both companies may receive tiered royalties on future sales.
Topics:businesshealthcare#ai-drug-discovery#benevolentai#exscientia#healthcare#immunology#merck-kgaa#neurology#oncology
- BenevolentAI, Exscientia on the comeback trail after securing separate AI drug discovery deals with Merck KGaA Endpoints News
- Merck KGaA doubles up on AI partners, tapping BenevolentAI and Exscientia for drug discovery push FierceBiotech
- Merck KGaA, Darmstadt, Germany, Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery Business Wire
- Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany Business Wire
- Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery Business Wire
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Endpoints News